BofA analyst Travis Steed reiterated a Buy rating and $115 price target on Boston Scientific (BSX), with the firm confirming that the Investigational Device Exemption study evaluating the LAMINAR Left Atrial Appendage Elimination, or LAAX, device was voluntarily paused. The firm thinks this is a positive update for Boston Scientific given their Watchmen Left Atrial Appendage Closure, or LAAC, device has 90% share of this market and will now have m ore time before it has competition from Johnson & Johnson (JNJ). It could also potentially help Boston Scientific’s share gains in Electrophysiology/Afib given the overlap between farapulse ablations and LAAC, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific, Medtronic, Constellation, Abbott, EOG Trending by Analysts
- Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
- Boston Scientific initiated with an Outperform at Leerink
- Boston Scientific’s Strong Market Position and Innovative Pipeline Drive Buy Rating
- Boston Scientific’s Growth Potential Remains Strong Despite Product Discontinuation